A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis

We evaluated the efficacy, pharmacokinetics, and safety of adalimumab in Japanese patients with active ankylosing spondylitis (AS) who had an inadequate response to, or who were intolerant of, treatment with ≥1 nonsteroidal anti-inflammatory drugs (NSAIDs). This phase 3, multicenter, open-label tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Shigeto, Harigai, Masayoshi, Mozaffarian, Neelufar, Pangan, Aileen L., Sharma, Shringi, Brown, L. Steven, Miyasaka, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3416976/
https://www.ncbi.nlm.nih.gov/pubmed/22205117
http://dx.doi.org/10.1007/s10165-011-0557-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3416976/
https://www.ncbi.nlm.nih.gov/pubmed/22205117
http://dx.doi.org/10.1007/s10165-011-0557-x

Ejemplares similares